Thanks for clearing that up - re-listened to the call and you are correct, Silviu did indeed suggest a possible pathway was phase 3 trials post approval from the FDA. This seems like a very intelligent way to move forward for treatments for the most unmet needs... rather than wait 6-12 months post trials for approval ... conditional approval is given while the trial is ongoing and once complete and agreed endpoints are met ... BOOOM - off to market!
I guess its up to MSB now and how well they can package the RA program ... next step would be to discuss these results with the FDA and see what partners are ready to tango!
Two GREAT takeaways, page-9
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.30 | $1.17 | $21.32M | 17.21M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 5460 | $1.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.26 | 978 | 1 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |